Keyphrases
Invadopodia
94%
Tyrosine Kinase 2 (TYK2)
76%
Metastatic Breast Cancer
74%
Hepatitis C Virus
74%
Clinical Trials
59%
Restricted Mean Survival Time
53%
Oncology Trials
49%
Randomized Controlled Trial
46%
Cancer Clinical Trials
45%
Invadopodia Formation
44%
Overall Survival
43%
Metastatic Melanoma
40%
Polyproline
39%
Hepatitis C Virus Infection
39%
Helix
38%
Cortactin
38%
Derived Peptide
37%
Immune Checkpoint Inhibitors
37%
Malignant Pleural Mesothelioma
37%
Lock-and-key Model
37%
Oncology Clinical Trials
37%
Numerical Analysis
37%
Saphenous Vein Graft
37%
Pharmacovigilance Analysis
37%
COVID-19
37%
SH3 Domain
33%
Reporting Odds Ratio
32%
Oncology
31%
Hepatocellular Carcinoma
30%
Sensitivity Analysis
30%
Nivolumab
30%
Confidence Interval
30%
Randomized Clinical Trial
29%
Odds Ratio
27%
Control Arm
27%
Kaplan-Meier
27%
Survival Outcomes
27%
Hazard Ratio
26%
Programmed Death-ligand 1 (PD-L1)
25%
Adverse Events
25%
Melanoma Patients
24%
Ipilimumab
24%
Surrogate Endpoint
23%
Angiotensin-converting Enzyme 2 (ACE2)
23%
Receptor Tyrosine Kinase
23%
Anti-PD-1
23%
Melanoma
22%
Fragility Index
21%
Informative Censoring
21%
Matrix Metalloproteinases
21%
Medicine and Dentistry
Clinical Trial
100%
Oncology
55%
Malignant Neoplasm
41%
Metastatic Carcinoma
41%
Breast Cancer
37%
Hepatitis C Virus
37%
Saphenous Vein Graft
37%
Randomized Clinical Trial
37%
Pleura Mesothelioma
37%
Overall Survival
27%
Cross Sectional Study
26%
Adverse Event
24%
Hemodynamic
24%
Hepatitis C
23%
Metastatic Melanoma
22%
Lymphocyte
20%
Ipilimumab
20%
Nivolumab
20%
Infection
20%
Neoplasm
19%
Receptor
18%
T Cell
18%
Vein Formation (Physiology)
18%
Thorax Surgery
18%
Hepatocyte
18%
Intimal Hyperplasia
18%
Mixed Infection
18%
Oncogene
18%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
Angiotensin Converting Enzyme 2
18%
Immune Checkpoint Inhibitor
18%
Vesicular Acetylcholine Transporter
18%
Cell Therapy
18%
Treatment Effect
18%
Virtual Screening
18%
Subgroup Analysis
18%
Mouth Inflammation
18%
Cisplatin
18%
Myeloid Cell
18%
Leukemia
18%
Congenital Myasthenic Syndrome
18%
Mouth Squamous Cell Carcinoma
18%
Colonoscopy
18%
Antiviral Drug
18%
NMR Spectroscopy
18%
Pemetrexed
16%
Survival Time
14%
Tumor Necrosis Factor
13%
Intention-to-Treat Analysis
12%
Whole Body Radiation
11%